Rejuvenate Bio was founded with the core mission of developing innovative gene therapies to treat aging and age-related diseases. The company's vision is to reverse aging and address multiple chronic conditions through targeted genetic interventions. Initially focusing on treatments for dogs, Rejuvenate Bio aims to expand its market to include therapies for humans suffering from chronic diseases, which are significant contributors to mortality and healthcare costs in the United States.
Notable affiliated individuals include co-founders George Church, a prominent geneticist, and Noah Davidsohn, who has extensive experience in gene therapy research. The company has attracted investment from leading biotech venture capital firms. Key achievements include successful preclinical trials demonstrating the efficacy of their gene therapies in animal models. Rejuvenate Bio's impact lies in its potential to revolutionize the treatment of chronic diseases and significantly extend healthy lifespans.
